OBJECTIVE: The purpose of this study was to evaluate whether oral naproxen or transdermal estradiol decreases bleeding and spotting in women who are initiating the levonorgestrel-releasing intrauterine system. STUDY DESIGN: We conducted a randomized controlled trial of naproxen, estradiol, or placebo that was administered over the first 12 weeks of levonorgestrel-releasing intrauterine system use. Participants completed a written bleeding diary. We imputed missing values and performed an intention-to-treat analysis. RESULTS: There were 129 women who were assigned randomly tonaproxen (n = 42 women), estradiol (n = 44 women), orplacebo (n = 43 women). The naproxen group was more likely to be in the lowest quartile of bleeding and spotting days compared with placebo (42.9% vs 16.3%; P = .03). In the multivariable analysis, the naproxen group had a 10% reduction in bleeding and spotting days (adjusted relative risk, 0.90; 95% confidence interval, 0.84-0.97) compared with placebo. More frequent bleeding and spotting was observed in the estradiol group (adjusted relative risk, 1.25; 95% confidence interval, 1.17-1.34). CONCLUSION: The administration of naproxen resulted in a reduction in bleeding and spotting days compared with placebo.
RCT Entities:
OBJECTIVE: The purpose of this study was to evaluate whether oral naproxen or transdermal estradioldecreases bleeding and spotting in women who are initiating the levonorgestrel-releasing intrauterine system. STUDY DESIGN: We conducted a randomized controlled trial of naproxen, estradiol, or placebo that was administered over the first 12 weeks of levonorgestrel-releasing intrauterine system use. Participants completed a written bleeding diary. We imputed missing values and performed an intention-to-treat analysis. RESULTS: There were 129 women who were assigned randomly to naproxen (n = 42 women), estradiol (n = 44 women), or placebo (n = 43 women). The naproxen group was more likely to be in the lowest quartile of bleeding and spotting days compared with placebo (42.9% vs 16.3%; P = .03). In the multivariable analysis, the naproxen group had a 10% reduction in bleeding and spotting days (adjusted relative risk, 0.90; 95% confidence interval, 0.84-0.97) compared with placebo. More frequent bleeding and spotting was observed in the estradiol group (adjusted relative risk, 1.25; 95% confidence interval, 1.17-1.34). CONCLUSION: The administration of naproxen resulted in a reduction in bleeding and spotting days compared with placebo.
Authors: Daniel R Mishell; John Guillebaud; Carolyn Westhoff; Anita L Nelson; Andrew M Kaunitz; James Trussell; Ann Jeanette Davis Journal: Contraception Date: 2006-10-11 Impact factor: 3.375
Authors: Gina M Secura; Jenifer E Allsworth; Tessa Madden; Jennifer L Mullersman; Jeffrey F Peipert Journal: Am J Obstet Gynecol Date: 2010-06-11 Impact factor: 8.661
Authors: Siripanth Nippita; Johana D Oviedo; Margarita G Velasco; Carolyn L Westhoff; Anne R Davis; Paula M Castaño Journal: Contraception Date: 2015-09-09 Impact factor: 3.375
Authors: Melanie H Jacobson; Penelope P Howards; James S Kesner; Juliana W Meadows; Celia E Dominguez; Jessica B Spencer; Lyndsey A Darrow; Metrecia L Terrell; Michele Marcus Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958